Trial · NCT07904754
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
NCT07904754, Phase 2, Not yet recruiting, AbbVie
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis. Trials, record NCT07904754. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904754
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
- NCT number
- NCT07904754
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 250 participants, estimated
- Lead sponsor
- AbbVie
- Conditions
- Rheumatoid Arthritis
- Interventions
- ABBV-722, Upadacitinib
- First posted
- 2026-10-29
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Achieving ACR50 Response | Week 12 | The ACR50 response is defined as at least 50% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis. The ACR50 response requires at least 50% improvement in tender and swollen joint counts and at least 50% improvement in at least 3 of the following 5 measures: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function (HAQ-DI), and acute phase reactant (CRP or ESR). |
| Primary | Number of Participants Experiencing Adverse Events | Up to 80 Weeks | An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
| Secondary | Percentage of Participants Achieving ACR20 Response | Week 12 | ACR20 response is defined as at least 20% improvement from Baseline in the American College of Rheumatology (ACR) core criteria, which includes tender joint count, swollen joint count, patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, and acute phase reactant (C-reactive protein or erythrocyte sedimentation rate). |
| Secondary | Percentage of Participants Achieving ACR70 Response | Week 12 | ACR70 response is defined as at least 70% improvement from Baseline in the American College of Rheumatology (ACR) core criteria, which includes tender joint count, swollen joint count, patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, and acute phase reactant (C-reactive protein or erythrocyte sedimentation rate). |
| Secondary | Percentage of Participants Achieving Low Disease Activity Based on DAS28 (CRP) <= 3.2 | Week 12 | Low Disease Activity (LDA) is defined as a Disease Activity Score 28 using C-reactive protein (DAS28 \[CRP\]) of \<= 3.2. DAS28 (CRP) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity. |
| Secondary | Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) < 2.6 | Week 12 | Clinical Remission (CR) is defined as a Disease Activity Score 28 using C-reactive protein (DAS28 \[CRP\]) of \< 2.6. DAS28 (CRP) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity. |
| Secondary | Percentage of Participants with a Change From Baseline in DAS28 (CRP) | Baseline to Week 12 | Disease Activity Score 28 using C-reactive protein (DAS28 \[CRP\]) is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and C-reactive protein. Scores range from 0 to approximately 10, with higher scores indicating more disease activity. A negative change from Baseline indicates improvement. |
| Secondary | Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) <= 10 | Week 12 | Low Disease Activity (LDA) is defined as a Clinical Disease Activity Index (CDAI) of \<= 10. CDAI is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76, with higher scores indicating more disease activity. |
| Secondary | Percentage of Participants Achieving Clinical Remission Based on CDAI <= 2.8 | Week 12 | Clinical Remission (CR) is defined as a Clinical Disease Activity Index (CDAI) of \<= 2.8. CDAI is a composite score derived from tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity, and physician's global assessment of disease activity. Scores range from 0 to 76, with higher scores indicating more disease activity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904754
GET https://conductscience.org/api/trials/v1/NCT07904754/registered